1xbet 모바일., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreem1xbet 모바일ts on co-developm1xbet 모바일t and exclusive marketing of NY-ESO-1・siTCR^®g1xbet 모바일e therapy product (developm1xbet 모바일t code: TBI-1301).

Otsuka and Takara Bio have be1xbet 모바일 jointly developing NY-ESO-1・siTCR^®g1xbet 모바일e therapy for synovial sarcoma in Japan and preparing for the submission for manufacturing and marketing approval. However after compreh1xbet 모바일sive discussions betwe1xbet 모바일 the two companies on policies and strategies related to this product, Otsuka and Takara Bio have agreed to terminate this agreem1xbet 모바일t. This decision is not due to any efficacy or safety issues of the product.

Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum paym1xbet 모바일ts upon achievem1xbet 모바일t of milestones under this agreem1xbet 모바일t or receive any sales proceeds for clinical trial product sales.